Harsh Kamlesh Kumar, Kapoor Akhil, Paramanandhan Murali, Narayan Satya, Purohit Ramesh, Kumari Pramila, Singhal Mukesh Kumar
Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment & Research Institute, Bikaner, Rajasthan India.
Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment & Research Institute, Bikaner, Rajasthan India ; Room No. 73, PG Boys Hostel, PBM Hospital Campus, Bikaner, 334003 Rajasthan India.
J Obstet Gynaecol India. 2016 Oct;66(5):372-8. doi: 10.1007/s13224-015-0699-4. Epub 2015 May 1.
The data of survival for Indian cervical cancer patients treated by indigenous modifications of the protocol are scarce. The objective of this retrospective study was to analyze the efficacy and tolerability in patients of cervical carcinoma treated by neoadjuvant chemotherapy followed by concurrent chemoradiation.
Three hundred and thirty two cases of squamous cell carcinoma of cervix who received 3 cycles of neoadjuvant chemotherapy followed concurrent chemoradiation were retrospectively analyzed for overall survival (OS), disease-free survival (DFS), and local pelvic control rate.
The 3-year OS and DFS were 93.7 % for stage I-B, 88.0 and 84.0 % for stage II-A, 82.8 and 79.7 % for stage II-B, 70.0 and 64.9 % for stage III-A, 59.3 and 52.4 % for stage III-B, and 53.6 and 32.1 % for stage IV-A disease. The 5-year OS and DFS rates were 93.7 and 87.5 % for stage I-B, 84.0 % for Stage II-A, 79.7 and 76.6 % for stage II-B, 67.6 and 59.5 % for stage III-A, 48.4 and 41.9 % for stage III-B, and 28.6 and 14.3 % for stage IV-A disease.
Neoadjuvant chemotherapy followed by concurrent chemoradiation is feasible and produces impressive disease-free and overall survival. This protocol is especially helpful for busy cancer centers with long waiting lists on radiotherapy machines.
关于采用本土改良方案治疗的印度宫颈癌患者的生存数据稀缺。本回顾性研究的目的是分析新辅助化疗后同步放化疗治疗宫颈癌患者的疗效和耐受性。
回顾性分析332例接受3周期新辅助化疗后同步放化疗的宫颈鳞状细胞癌患者的总生存期（OS）、无病生存期（DFS）和局部盆腔控制率。
I - B期患者的3年总生存期和无病生存期分别为93.7%，II - A期为88.0%和84.0%，II - B期为82.8%和79.7%，III - A期为70.0%和64.9%，III - B期为59.3%和52.4%，IV - A期为53.6%和32.1%。I - B期患者的5年总生存期和无病生存期分别为93.7%和87.5%，II - A期为84.0%，II - B期为79.7%和76.6%，III - A期为67.6%和59.5%，III - B期为48.4%和41.9%，IV - A期为28.6%和14.3%。
新辅助化疗后同步放化疗是可行的，且能产生令人印象深刻的无病生存期和总生存期。该方案对放疗设备等待名单长的繁忙癌症中心尤其有帮助。
